If you've been investing in process improvements, new product development, or engineering upgrades at your facility, the federal tax treatment of those costs just changed — significantly. For three years, the Tax Cuts and Jobs Act (TCJA) forced manufacturers to spread their domestic R&D deductions over five years instead of taking them all at once. The result? Higher taxable income, bigger tax bills, and less cash to reinvest on the shop floor. According to the National Science Foundation, manufacturers account for roughly 60% of all U.S. business R&D spending — which means this rule has been costing manufacturing companies billions in deferred deductions since 2022. The One Big Beautiful Bill Act (OBBBA), signed into law on July 4, 2025, changed the game. This guide breaks down exactly what changed, what it means for your 2025 tax bill, and what actions you need to take right now.
Before 2022, Section 174 of the tax code was simple: if you spent money on qualifying research and experimentation (R&E), you deducted it in the same year. Clean and straightforward.
The TCJA flipped that. Starting with tax years beginning after December 31, 2021, all domestic R&D costs had to be capitalized and amortized over five years — 15 years for any research conducted outside the U.S. The mid-year convention rule made it worse: only half a year's worth of amortization was allowed in year one.
Here's what that looked like in practice. Suppose your engineering team spent $500,000 improving a production process in 2022. Under the old pre-TCJA rules, you'd deduct the full $500,000 that year. Under the TCJA rules, you deducted just $50,000 in year one. The remaining $450,000 got spread over the following four-plus years.
That's not a small accounting technicality. That's a real cash flow impact — higher taxable income, higher estimated tax payments, and less working capital available to grow your business.
For manufacturers who invest heavily in product development, tooling improvements, software, and process engineering, the compounding effect across 2022, 2023, and 2024 was substantial.
The OBBBA, signed July 4, 2025, effectively reversed the TCJA's R&D capitalization requirement for domestic expenses. It created a new code section — IRC Section 174A — that restores immediate expensing for domestic R&E costs.
Starting with tax years beginning after December 31, 2024, you can now fully deduct domestic research and experimental expenditures in the same year you spend the money. The mandatory five-year amortization schedule is gone for U.S.-based research.
This change is part of the 2025 tax reform signed into law on July 4, 2025, as P.L. 119-21, and it reverses the capitalization requirement introduced under the TCJA, restoring a more favorable approach for companies investing in innovation.
There is one important geographic carve-out: research or experimental expenditures attributable to research conducted outside the United States must continue to be capitalized and amortized over 15 years. If any of your R&D work is done offshore or through foreign contractors, those costs are still subject to the old long-amortization rules.
The practical upshot for most domestic manufacturers: your 2025 R&D tax deductions just got much larger, and your effective tax rate dropped.
This is where a lot of manufacturing owners leave money on the table — they assume R&D means white-coat lab research. It doesn't.
Section 174 defines qualifying R&E expenditures broadly. For manufacturers, costs that typically qualify include:
The key legal standard is "technical uncertainty" — the work must involve attempting to eliminate uncertainty about whether something can be developed or how to develop it. Routine production work doesn't qualify. But a surprising amount of what happens in manufacturing engineering does.
If your financial management control process isn't already tracking R&D labor and materials separately from standard production costs, now is the time to build that structure. The IRS requires documentation, and without it, your deductions are vulnerable.
Here's where things get genuinely interesting for smaller manufacturers. The OBBBA didn't just fix the rules going forward. It created a path to recover overpaid taxes from 2022 through 2024.
Small businesses with average annual gross receipts of $31 million or less may elect to apply the Section 174 fix retroactively to tax years beginning after December 31, 2021, by amending all affected prior returns for 2022, 2023, and 2024. That means if your company qualifies, you could file amended returns and potentially receive refunds for taxes paid on R&D costs that should have been fully deductible.
Deadline alert: Amended returns must be filed by the earlier of July 6, 2026, or the statute of limitations for claiming a refund. That window is not far off.
One important condition: you must amend all affected years together. You can't cherry-pick 2023 but skip 2022. And if you claimed the Section 41 R&D Tax Credit in any of those years, there's an interaction effect that requires careful analysis — the deduction and the credit partially offset each other, so the net benefit needs to be modeled for your specific situation.
If you're not sure whether the retroactive path makes sense for your business, this is exactly the kind of analysis a fractional CFO can run for you before the deadline hits.
Need help figuring out whether your R&D spending qualifies — or whether retroactive amendments make sense for your situation? Accounovation works with manufacturing business owners to identify deduction opportunities and build clean financial records that hold up under scrutiny. Contact us to get a clear picture of where you stand before the filing deadline.
If your company exceeds $31 million in average annual gross receipts, you don't qualify for the retroactive amendment path. But you still have options — and they're worth acting on quickly.
For unamortized domestic R&D costs from 2022–2024, larger businesses have three options: deduct the full remaining balance in the 2025 tax return, spread it evenly over 2025 and 2026, or continue amortizing under the original schedule.
The right choice depends heavily on your projected taxable income for 2025 and 2026. Accelerating deductions into 2025 makes sense if you expect strong profitability that year — the deduction shields more income. If you anticipate a leaner year or a significant capital expenditure that will already reduce taxable income, spreading the deduction over two years may produce better results.
This is not a one-size-fits-all calculation. Deductions are generally more valuable than net operating losses, because post-2017 NOLs are limited to offsetting 80% of taxable income. Burning a large deduction in a low-income year can mean getting less value from it than if you'd timed it differently. Your tax strategy and your cash flow forecasting need to be coordinated here.
One mistake to avoid: assuming that because you now get the full Section 174 deduction, you don't need to bother with the Section 41 R&D Tax Credit. That logic will cost you.
The Section 174 deduction and the Section 41 credit are two separate tax benefits that work differently. The deduction reduces your taxable income. The credit directly reduces your tax bill dollar-for-dollar — which is significantly more powerful. For profitable manufacturers, the credit can be worth tens or hundreds of thousands of dollars annually.
The interaction between the two requires a bit of math. Under IRC Section 280C, if you claim the full credit, you must reduce your deductible R&D expenses by the amount of the credit. That reduces the deduction slightly but doesn't eliminate it. For most companies, the combined value of taking both is still far greater than the deduction alone.
The key requirement: documentation. The IRS has tightened its Form 6765 requirements and is actively auditing R&D credit claims. You need to be able to show which employees worked on qualifying projects, for how many hours, and what the nature of the technical uncertainty was. Build that documentation system now — before you file.
It's not just your tax return that's affected by these changes. If your company capitalized R&D expenses on your books during 2022–2024 in accordance with GAAP, you may need to assess whether your deferred tax asset balances need to be updated to reflect the new rules.
Companies that capitalized R&E costs for book purposes may need to reassess deferred tax assets and liabilities. This is particularly relevant if you're using your financials to pursue financing, prepare for acquisition discussions, or report to outside investors. Stale deferred tax balances can distort the picture your financial statements present.
On the cash flow side, the immediate expensing of R&D costs in 2025 means lower taxable income and lower estimated tax payments — which translates directly to more cash staying in the business through the year. For manufacturers who've been squeezing their working capital to cover quarterly tax installments, this is meaningful relief.
Build the Section 174A benefit into your 2025 financial projections now. Don't wait until year-end to discover you've been over-paying quarterly estimates.
At Accounovation, we work with manufacturing business owners to turn complex tax law changes into concrete financial action — not just compliance checkboxes. The Section 174 changes represent a real opportunity: potential refunds from prior years, lower 2025 tax liability, and a stronger cash position going forward. But capturing that value requires clean cost tracking, careful election analysis, and coordination between your tax strategy and your financial projections.
From Fractional CFO services that integrate tax planning into your overall financial strategy, to Cash Flow Management and Budgeting and Forecasting that reflect your true 2025 tax position, we help you move quickly and accurately. Contact us today to make sure you're not leaving money on the table before the retroactive filing deadline closes.
Does my manufacturing company qualify for the Section 174A immediate expensing benefit?
If your company conducts domestic research and experimentation — including process improvement engineering, new product development, custom software, or prototype testing — you likely have qualifying R&E expenditures. The Section 174A immediate expensing applies to all businesses for domestic R&D costs incurred in tax years beginning after December 31, 2024. Smaller businesses (under $31M in average gross receipts) may also qualify for retroactive relief on 2022–2024 costs. A qualified advisor can review your cost records and confirm what qualifies.
What's the deadline to file amended returns and claim retroactive Section 174 refunds?
If your company qualifies as a small business (average annual gross receipts of $31 million or less over the prior three years), you can amend your 2022, 2023, and 2024 tax returns to reclaim deductions that were previously spread over five years. The amended returns must be filed by July 6, 2026, or the applicable statute of limitations — whichever comes first. You cannot pick individual years; all affected years must be amended together. Given the complexity of the Section 280C interaction with R&D credits, work with an advisor before filing.
How do I start tracking R&D costs properly in my manufacturing business?
Start by identifying every project that involves technical uncertainty — meaning your team isn't certain at the outset whether or how something can be accomplished. For each qualifying project, track employee time spent on that work separately from routine production, capture material costs used in testing or experimentation, and document the technical question each project was trying to answer. Your accounting system should have separate cost codes for R&D activity. The IRS requires this level of detail to support both the Section 174 deduction and any Section 41 R&D Tax Credit claim.